ISSN: 1307-5888 | E-ISSN: 2757-7392 | Contact
The risk of development of primary biliary cholangitis among incidental antimitochondrial M2 antibody-positive patients
1Department of Gastroenterology, School of Medicine, Marmara University, Istanbul, Turkiye
2School of Medicine, Marmara University,, Istanbul, Turkiye
3Department of Gastroenterology, Rize Training and Research Hospital, Recep Tayyip Erdogan University; Rize, Turkiye
4Department of Gastroenterology, School of Medicine, Marmara University, Istanbul, Turkiye; Institute of Gastroenterology, Marmara University, Istanbul, Turkiye; Department of Gastroenterology, School of Medicine, Recep Tayyip Erdogan University, Rize, Turkiye
Hepatology Forum 2023; 4(2): 69-73 DOI: 10.14744/hf.2023.2023.0016 PMCID: PMC10209978
Full Text PDF


Background and Aim: This study investigated the risk of the development of primary biliary cholangitis (PBC) in individuals who were incidentally identified as having positive antimitochondrial antibodies (AMA)-M2.
Material and Methods: We retrospectively reviewed extractable nuclear antibody (ENA) panel test results to identify the incidental AMA-M2-positive patients. Patients who filled the diagnostic criteria for PBC were excluded. AMA-M2-positive patients were further evaluated by physical examination, liver biochemistry, liver ultrasonography, and transient elas-tography (TE) and were also closely followed.
Results: We included 48 (n=45, 93% female) individuals with a median age of 49 (range: 20–69) years. The median follow-up duration was 27 months (range: 9–42) after the detection of AMA-M2. Thirty-three (69%) patients had concomitant autoimmune/inflammatory disorders. Twenty-eight (58%) individuals showed seropositivity for ANA, and 21 had (43%) positive AMA. Fifteen (31%) patients developed typical PBC according to the international PBC diagnostic criteria during the follow-up, and five of them (18%) had significant fibrosis (≥8.2 kPA) by TE at the time of PBC diagnosis.
Conclusion: Two-thirds of the incidental AMA-M2-positive patients devel-oped typical features of PBC after a median 27-month follow-up. Our re-sults suggest that AMA-M2 patients should be closely followed up to detect the late development of PBC.